Prior history of allergic reactions to G-CSF History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments; Patients who are allergic to milk Patient has a history of allergic reactions attributed to perillyl alcohol. History of allergic reactions attributed to components of the formulated product History of allergic reactions to any component of the IMP. History of allergic reactions attributed to cyclophosphamide or alemtuzumab EXCLUSION - INFUSION: History of allergic reactions attributed to nivolumab or any other checkpoint inhibitors History of allergic reactions attributed to oral vancomycin or oral polymyxin B A history of serious allergic reactions, which in the opinion of the investigator pose an increased risk of serious infusion reactions. History of allergic reactions to pralatrexate or romidepsin Hypersensitivity (history of allergic reactions) to History of allergic reactions or sensitivity to pyrimethamine History of allergic reactions to either azacitidine or ascorbic acid Patients with history of allergic or toxic reactions attributed to cytarabine or a history of allergic reactions to components of the formulated product Patients with history of allergic or toxic reactions attributed to anthracyclines or a history of allergic reactions to components of the formulated product Patients with known potentially anaphylactic allergic reactions to gadolinium-diethylenetriamine penta-acetic acid (DTPA) History of allergic reactions to SGI- or decitabine History of, or suspected allergic reactions to durvalumab, pralatrexate, oral -azacitidine, or romidepsin or any of their excipients History of severe allergic reactions (as determined by treating physician) attributed to the drugs being used in the study History of allergic reactions to products containing mouse and bovine protein antibodies. Known allergic reactions, irritations or sensitivity to the active ingredients or other components of SOR; Patients with a history of allergic reactions attributed to docetaxel or paclitaxel are ineligible Allergic reactions or acute hypersensitivity reaction attributed to antibody treatments Any known allergy or allergic reactions to Captisol History of allergic reactions to TGR- or carfilzomib History of uncontrollable allergic reactions to bevacizumab or ascorbic acid Patients with known potentially anaphylactic allergic reactions to gadolinium- diethylene triamine pentaacetic acid (DTPA) Allergic to temozolomide (TMZ) Patients who have known allergic reactions to paclitaxel or IV contrast dye despite standard prophylaxis History of allergic reactions attributed to doxorubicin or Doxil. History of uncontrollable allergic reactions to vitamin D Documented allergic reactions or similar to antibody treatments No life-threatening allergy to bakers yeast or other components of the vaccines; no history of allergic reactions to the antibiotics neomycin, streptomycin or polymyxin B ELIGIBILITY CRITERIA- LYMPHODEPLETION/INFUSION OF tvs-CTL: Must not have a life-threatening allergy to bakers yeast or other components of the vaccines; no history of allergic reactions to the antibiotics neomycin, streptomycin or polymyxin B Propensity to allergic reactions defined as a history of allergic reaction to more than one medication Have any known allergic reactions to any of the drugs or liposomal components or intravenous imaging agents that prohibit the ability to complete the imaging requirements. History of allergic reactions or hypersensitivity to the study drugs (hydroxychloroquine, gemcitabine, Abraxane) History of prior allergic reactions attributed to compounds of CT/MRI contrast that cannot be managed with appropriate pre-medication prophylaxis and thereby preclude use of baseline/ follow-up or radiation planning imaging History of allergic reactions to recombinant IL- History of allergic reactions or intolerance to any of the required agents on the study History of allergic reactions attributed to metformin or other biguinides Patients who have known allergic reactions to IV contrast dye despite standard prophylaxis Known sensitivity or allergic reactions to acyclovir or valacyclovir History of allergic reactions to mouse antigens History of allergic reactions to any components of the treatments History of allergic reactions to cetuximab. Has history of asthma, or other allergic-type reactions after taking aspirin or other NSAIDs History of allergic reactions to chemotherapy agents used in this protocol as part of lymphodepletion regimen (fludarabine and cyclophosphamide) History of severe allergic reactions attributed to any vaccine therapy for the prevention of infectious diseases History of severe allergic reactions attributed to any vaccine therapy for the prevention of infectious diseases History of allergic or idiosyncratic/hypersensitivity reactions to -methoxypsoralen/psoralen compounds Patients who are allergic to micafungin and/or voriconazole or any of their ingredients History of allergic reactions or intolerance to any of the required agents on the study Known history of allergic reactions to paclitaxel History of allergic reactions attributed to riluzole or sorafenib Patients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds; patients with allergic (hypersensitivity) reactions to these chemotherapeutic agents are NOT excluded IF they were successfully retreated following a desensitization program or protocol History of allergic reactions to carboplatin, platinum containing compounds or mannitol and/or hypersensitivity to PLD or to any of the excipients History of allergic reactions to Cremophor EL, paclitaxel or its components Patients with prior grade allergic or infusion reactions to docetaxel, cisplatin or cetuximab are not eligible; a history of well tolerated infusion reactions is NOT an exclusion History of clinically significant allergic reactions or atopic disease that may pose an increased risk of severe CDX- IRRs. History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis Patients with a history of grade allergic reactions to anti-GD antibodies or reactions that required discontinuation of the anti-GD therapy are not eligible History of allergic reactions to imiquimod or its excipients History of allergic reactions attributed to therapeutic antibodies; Note: patients with reactions to chimeric antibodies may be permitted on a case by case basis with approval by study chair by contacting the data manager Patients with known potentially anaphylactic allergic reactions to gadolinium-diethylenetriamine penta-acetic acid (DTPA) Patients with a history of allergic reactions attributed to eribulin or irinotecan History of uncontrollable allergic reactions to temozolomide or ascorbic acid or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy Any previous treatment with LDE or allergic reactions to excipients of LDE History of allergic reactions attributed to thalidomide or lenalidomide History of allergic reactions to oral -azacitidine or romidepsin History of allergic reactions attributed to fluoropyrimidine (e.g., capecitabine, fluorouracil, fluorodeoxyuridine) or tetrahydrouridine History of serious allergic reactions to pegfilgrastim or filgrastim History of allergic reactions to bacterially-produced proteins History of allergic reactions to medicines containing polyoxyethylated castor oil that are not controlled with premedications History of allergic reactions attributed to trastuzumab (cohorts , ) that were not treatable/preventable with pre-medications or desensitization protocols Acute allergic disorders or a history of severe allergic reactions History of anaphylaxis or serious allergic reactions to previous administration of any of the vaccines Patients who have known allergic reactions to paclitaxel or IV contrast dye despite standard prophylaxis History of allergic reactions attributed to fluoropyrimidines (e.g., capecitabine, fluorouracil, fluorodeoxyuridine) or tetrahydrouridine Patients with a history of serious allergic reactions History of allergic reactions attributed to components of the formulated product(s) Generalized dermatologic conditions (such as allergic reactions, infection, edema, or scarring) that will not allow for study drug administration at a site of normal skin or evaluation of localized adverse events History of allergic reactions to anilinoquinazolins like gefitinib, erlotinib, or BIBW History of allergic or toxic reactions attributed to cytarabine (Part ) or history of allergic reactions to components of the formulated product Subjects with a history of allergic reactions to lactose. Contraindication to steroid use or history of allergic reactions attributable to the study compounds History of allergic reactions to bacterially-produced proteins History of allergic reactions to the study drugs, their analogs or any component of the products History of reactions to liposomal drug formulations other than PLD should be evaluated individually and if their reactions were felt to have been due to the encapsulated agent, rather than the liposomal component itself they should be excluded at the discretion of the investigators The patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product. History of allergic reactions to quinalones or chloroquine. Patients with history of life threatening allergic reactions to food or drugs History of allergic reactions attributed to compounds chemically related to lapatinib (quinazolines), capecitabine, fluorouracil or any excipients; The patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product. Previous allergic reactions to dexamethasone. History of allergic reactions to whey or milk proteins Must not have a contraindication for using lidocaine: e.g. no history of allergic reactions to lidocaine History of allergic reactions to whey protein Subjects with history of allergic reactions to ketamine Allergic to yogurt History of allergic or other adverse reactions to minocycline History of allergic or other adverse reactions to tetracycline A history of allergic reactions attributed to either Monocryl suture or stainless steel staples Previous allergic reactions to dexamethasone Prior significant allergic reactions to drugs containing Cremophor, such as cyclosporine, or vitamin K are not eligible; a significant reaction may be defined as, but is not limited to, the description of grade = allergic reactions using the Common Toxicity Criteria (CTC) Not be allergic to any cruciferous vegetables (e.g.: broccoli, cauliflower, kale, brussels sprouts, arugula/rocket, bok choy, etc.) Evidence or history of clinically significant allergic reactions to varenicline History of allergic reactions attributed to naproxen Have a history of allergic reactions to metformin or similar drugs Evidence or history of clinically significant allergic reactions to varenicline History of allergic reactions or hypersensitivity to ketamine There will be no exclusion requirements due to co-morbid disease or incurrent illness\r\n* History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study Since the diagnostic MR examination does not require injection of contrast agent there will be no specific requirements regarding history of allergic reactions History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigators discretion Known allergic reactions to components of the study product(s) Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigators discretion Patients with contraindications to the use of intravenous contrast such as allergic type reactions History of multiple or severe allergic reactions attributed to immunoglobulins or MRI contrast agents Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigators discretion Allergic to common dentifrice ingredients Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion History of allergic reactions to INCB, any of the excipients of INCB or similar compounds. Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals (patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigators discretion) No restrictions on allergic reactions as no imaging agent will be used History of allergic reactions attributed to ICG or other agents used in the study, including known iodide or seafood allergy History of allergic reactions attributed to azacitidine Patients may not have a history of severe allergic reactions to paclitaxel or other drugs formulated in cremaphor EL History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization.